New Clinical Study Shows Limbrel™ is an Effective G.I. Friendly Alternative to Naproxen
November 16, 2007
FOR IMMEDIATE RELEASE


New Clinical Study Shows Limbrel™ is an Effective G.I. Friendly Alternative to Naproxen for Knee Osteoarthritis


SCOTTSDALE, Ariz. – Nov. 16, 2007 Physicians now have good news for their osteoarthritis patients, especially those who want to avoid gastrointestinal (GI) side-effects.

Findings presented last Thursday at the American College of Rheumatology in Boston, showed a dramatic increase in serious gastrointestinal complications that can lead to bleeding, hospitalization or even death as patients and physicians have been forced to use more naproxen (Aleve®) and ibuprofen (Advil®) for osteoarthritis pain since the withdrawal of Vioxx and similar drugs.

A recent clinical study compared a prescription product called Limbrel with naproxen. Limbrel was shown as effective as naproxen in providing overall improvement, including mobility, stiffness and joint discomfort for knee osteoarthritis. The difference is that Limbrel addresses the underlying metabolic cause rather than just treating the symptoms, minimizing the risk of serious GI side effects associated with other prescriptions.

The Limbrel versus naproxen clinical study was presented at the 7th International Cartilage Repair Society World Congress recently held in Warsaw, Poland. The results showed there is a GI friendly choice that is effective for osteoarthritis patients.

Osteoarthritis is the number one cause of disability in the United States affecting more than 25 million Americans, or one in 8 adults. Once commonly thought to be a wear-and-tear or aging disease, recent evidence suggests that there are metabolic factors involved in worsening damage to joints over time.

Limbrel is a prescription medical food product for the clinical dietary management of the metabolic processes of osteoarthritis. For more information on Limbrel, please visit www.limbrel.com

About Primus Pharmaceuticals, Inc.
Primus is the first pharmaceutical company to focus on prescription metabolic products dedicated to improving patient quality of life without compromising safety. Primus develops branded prescription drugs and medical foods that are proven safe and effective in chronic or recurring diseases. The Company’s needs-based process to develop first-line prescription products formulated to restore metabolic processes at the disease source (rather than masking symptoms) is novel and proprietary. Primus promotes to targeted physician specialists and extends its sales reach and clinical capabilities through strategic partnerships. All products are protected by composition of matter patents and other intellectual property. Primus is privately held and based in Scottsdale, AZ. For more information, visit www.primusrx.com.


Forward-looking statement
This press release contains certain “forward looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent that any statements made in this press release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors. Primus cautions that any forward-looking information is not a representation or guarantee of future performance, and Primus assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.


Contacts
Media: Amendola Communications for Primus Pharmaceuticals
Jan Shulman, 480.664.8412, ext. 12
About the Press Release
A recent clinical study compared Limbrel with Naproxen. Limbrel was shown as effective as Naproxen, in providing overall improvement for knee osteoarthritis.


 
< Prev   Next >